Clinical trial
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
NCT03188393 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
- Lead sponsor
- NRG Oncology
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 13, 2017
- Completion date
- December 1, 2022
- Enrollment
- 105 (actual)
- Sites
- 381
Conditions
As the registry lists them; a condition with its own page is linked.
invasive breast carcinoma, stage ii breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer